Whole-body evaluation of MIBG tissue extraction in a mouse model of long-lasting type II diabetes and its relationship with norepinephrine transport protein concentration

Journal of Nuclear Medicine

Volumn 49, Issue 10, 2008, Pages 1701-1706

  Kusmic, Claudia ^a,d   Morbelli, Silvia ^b   Marini, Cecilia ^a   Matteucci, Marco ^c   Cappellini, Chiara ^c   Pomposelli, Elena ^b   Marzullo, Paolo ^a   L'Abbate, Antonio ^a,c   Sambuceti, Gianmario ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SCUOLA SUPERIORE SANT ANNA   (Italy)

^d CNR   (Italy)

Author keywords

Cardiac autonomic neuropathy; Mouse; Radiobinding; SPECT; Type II diabetes

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; DESIPRAMINE H 3; NORADRENALIN TRANSPORTER; RADIOPHARMACEUTICAL AGENT; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTONOMIC NEUROPATHY; BINDING ASSAY; BLADDER; BLOOD; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; EXTRACTION; FEMALE; HEART; HEART MUSCLE; INJECTION; KINETICS; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TIME; URINARY EXCRETION; WHOLE BODY IMAGING;

3-IODOBENZYLGUANIDINE; ANIMALS; BIOLOGICAL TRANSPORT; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; KINETICS; LIVER; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; NOREPINEPHRINE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 53749100350     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.054361     Document Type: Article

References (26)

1. Rathman W, Ziegler D, Jahnke M, Haastert B, Gries FA. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med. 1993; 10:1820-1824.
2. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med. 1980;49:95-108.
3. Zola B, Kahn JK, Juni JE, Vinik AI. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease. J Clin Endocrinol Metab. 1986;63:208-214.
4. Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care. 2001;24:1793-1798.
5. Nagamachi S, Fujita S, Nishii R, et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol. 2006;13:34-42.
6. Hattori N, Tamaki N, Hayashi T, et al. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med. 1996;37:1985-1990.
7. Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med. 2000;27:1-6.
8. Merlet P, Valette H, Dubois-Rande JL, et al. Iodine 123-labeled metaiodobenzylguanidine imaging in heart disease. J Nucl Cardiol. 1994;1(suppl):S79-S85.
9. Wieland DM, Brown LE, Rogers WL, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22:22-31.
10. Nakajo M, Shimabukuro K, Yoshimura H, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med. 1986;27:84-89.
11. Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med. 1987;28:1620-1624.
12. Tobes MC, Jaques S Jr, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985;26:897-907.
13. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med. 1993;34:1140-1146.
14. 123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol. 1995;22:1-12.
15. Ungerer M, Weig HJ, Kübert S, et al. Regional pre- and postsynaptic sympathetic system in the failing human heart: regulation of βARK-1. Eur J Heart Fail. 2000;2:23-31.
16. Sugiyama T, Kurata C, Tawarahara K, Nakano T. Is abnormal iodine-123-MIBG kinetics associated with left ventricular dysfunction in patients with diabetes mellitus? J Nucl Cardiol. 2000;7:562-568.
17. 123I]metaiodobenzylguanidine kinetics with heart rate variability and plasma norepinephrine level. J Nucl Cardiol. 1997;4:515-523.
18. Kiyono Y, Iida Y, Kawashima H, Ogawa M, Tamaki N, Nishimura H. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging. 2002;29:999-1005.
19. Kiyono Y, Kanegawa N, Kawashima H, et al. A new norepinephrine transporter imaging agent for cardiac sympathetic nervous function imaging: radioiodinated (R)-N-methyl-3-(2-iodophenoxy)-3-phenylpropanamine. Nucl Med Biol. 2003; 30:697-706.
20. Kiyono Y, Kajiyama S, Fujiwara H, Kanegawa N, Saji H. Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: implications for heterogeneous accumulation of MIBG. Eur J Nucl Med Mol Imaging. 2005;32:438-442.
21. Carrio I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42:1062-1076.
22. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553-1579.
23. Wei M, Ong L, Smith MT, et al. The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ. 2003;12:44-50.
24. Masiello P. Animal models of type 2 diabetes with reduced pancreatic β-cell mass. Int J Biochem Cell Biol. 2006;38:873-893.
25. 3H] desipramine binding associated with neuronal norepinephrine uptake sites in rat brain membranes. J Neurosci. 1982;2:1515-1525.
26. Taki J, Nakajima K, Hwang EH, et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med. 2000;27:566-573.